SQZ Biotechnologies Debt to Equity Ratio 2020-2023 | SQZ
Current and historical debt to equity ratio values for SQZ Biotechnologies (SQZ) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. SQZ Biotechnologies debt/equity for the three months ending March 31, 2023 was 0.00.
| SQZ Biotechnologies Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$0.03B |
$0.04B |
0.82 |
| 2022-12-31 |
$0.04B |
$0.06B |
0.75 |
| 2022-09-30 |
$0.09B |
$0.07B |
1.26 |
| 2022-06-30 |
$0.09B |
$0.09B |
1.05 |
| 2022-03-31 |
$0.10B |
$0.11B |
0.91 |
| 2021-12-31 |
$0.10B |
$0.12B |
0.82 |
| 2021-09-30 |
$0.11B |
$0.13B |
0.83 |
| 2021-06-30 |
$0.09B |
$0.15B |
0.56 |
| 2021-03-31 |
$0.09B |
$0.17B |
0.55 |
| 2020-12-31 |
$0.10B |
$0.13B |
0.82 |
| 2020-09-30 |
$0.11B |
$0.07B |
1.52 |
| 2020-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.017B |
$0.021B |
|
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
|
